PTC Therapeutics, Inc. (PTCT) News
Follow PTC Therapeutics, Inc. (PTCT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 32 public stories across 15 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
PTC Therapeutics Sets FY Revenue Outlook
PTC Therapeutics provided a full-year revenue outlook.
EARNINGS | Oct 29, 2026, 08:29 PM UTC
M
PTC Therapeutics Posts Q3 Net Loss
EQUITY | Oct 29, 2026, 08:18 PM UTC
M
PTC Therapeutics Swings to Q3 Net Loss of $51.69 Million
PTC Therapeutics reported a net loss of $51.69 million for Q3 2026, compared with a profit a year earlier.
EQUITY | Oct 29, 2026, 08:08 PM UTC
M
PTC Therapeutics Reports Q3 Operating Income of USD 25.114 Million
EARNINGS | Oct 29, 2026, 08:05 PM UTC
M
PTC Therapeutics Reports Third-Quarter Revenue of $357.8 Million
EQUITY | Oct 29, 2026, 08:05 PM UTC
M
PTC Therapeutics reports 3Q loss of $51.7 million
EARNINGS | Oct 29, 2026, 08:01 PM UTC
M
PTC Therapeutics Q3'26 Revenue Estimate Ahead of Results
PTC Therapeutics is set to report Q3'26 results on October 22; the report time is not specified.
EQUITY | Oct 15, 2026, 11:01 AM UTC
M
PTC Therapeutics completes acquisition of St-920 gene therapy fab
MNA | Sep 21, 2026, 09:02 PM UTC
M
PTC completes acquisition of ST-920 Fabry disease gene therapy
PTCT - PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
MNA | Sep 21, 2026, 08:44 PM UTC
H
PTCT: Sephience’s robust launch and global expansion drive raised guidance and pipeline momentum
Sephience’s launch is outperforming prior PKU therapies, driving raised revenue guidance and strong global expansion. Real-world data confirm broad patient benefit, while pipeline programs advance in Friedreich ataxia, H
EARNINGS | Sep 15, 2026, 03:41 PM UTC
H
PTCT: Sephience’s strong launch and global expansion drive raised guidance and future growth
Sephience’s launch is outperforming prior PKU therapies, driving raised revenue guidance and global expansion. Real-world and clinical data reinforce its broad applicability, while pipeline progress and a strategic acqui
EARNINGS | Sep 15, 2026, 02:27 PM UTC
L
PTC Therapeutics Price Target Announced at $98.00/Share by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 14, 2026, 09:07 PM UTC
L
PTCT: Broad PKU launch, strong pipeline, and global expansion drive growth and profitability
Management highlighted strong financials, broad PKU launch success, and a robust rare disease pipeline. International growth is expected to accelerate from 2026, with strategic pricing and reimbursement efforts underway.
EQUITY | Sep 10, 2026, 03:00 PM UTC
L
PTCT: Global rare disease growth driven by SUFIANCE, new assets, and disciplined financial strategy
Management highlighted strong financial positioning, global expansion of SUFIANCE, and a robust rare disease pipeline. Key growth drivers include international launches, new gene therapy assets, and disciplined operation
EQUITY | Sep 10, 2026, 02:33 PM UTC
L
PTC Therapeutics to buy drug candidate from Sangamo for up to $211M
PTC Therapeutics plans to buy a drug candidate from Sangamo for up to $211M.
EQUITY | Aug 28, 2026, 09:59 PM UTC
L
PTC Therapeutics to make $111M upfront payment, with up to $100M milestones
PTC Therapeutics will make an upfront payment of $111 million and may pay up to an additional $100 million in contingent milestone payments.
EQUITY | Aug 28, 2026, 09:42 PM UTC
M
PTC Therapeutics agrees to acquire Sangamo ST-920 Fabry assets
PTC Therapeutics agreed to acquire Sangamo assets primarily related to ST-920, an AAV gene therapy product candidate for Fabry disease.
MNA | Aug 28, 2026, 09:42 PM UTC
L
PTC Therapeutics enters asset purchase agreement with Sangamo
PTC Therapeutics entered into an asset purchase agreement with Sangamo Therapeutics.
EQUITY | Aug 28, 2026, 09:42 PM UTC
M
PTC Therapeutics to buy ST-920 Fabry gene therapy for $111M
PTC Therapeutics agreed to buy Sangamo’s ST-920 Fabry gene therapy for $111M, with $100M in milestones.
EQUITY | Aug 28, 2026, 08:15 PM UTC
L
PTCT - PTC Therapeutics to Participate in Upcoming Investor Conferences
PTCT - PTC Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Aug 27, 2026, 12:02 PM UTC
L
PTC Therapeutics presents new Sephience data
PTC Therapeutics says new Sephience (sepiapterin) data reinforce sustained metabolic control, diet liberalization and a consistent favorable safety profile.
EQUITY | Aug 24, 2026, 12:01 PM UTC
M
PTC Therapeutics plans ST-920 Fabry program acquisition
PTC Therapeutics says it will acquire Sangamo Therapeutics’ ST-920 Fabry disease program in a competitive bankruptcy auction for $111 million upfront plus up to $100 million in contingent milestone payments.
MNA | Aug 13, 2026, 04:28 PM UTC
H
PTC Therapeutics Acquires ST-920 Fabry Disease Program
PTC Therapeutics is acquiring the BLA-stage ST-920 Fabry disease program for $111M upfront and up to $100M in contingent milestone payments
MNA | Aug 12, 2026, 08:14 PM UTC
H
PTC Expands Rare Disease Portfolio
PTC acquires BLA-stage ST-920 Fabry disease program
MNA | Aug 12, 2026, 08:02 PM UTC
L
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Aug 04, 2026, 10:04 AM UTC
H
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1
AXTI +20%, COHU +15.7%, FND +11.2%, MPWR +9.8%, RYAN +9.1%, AMZN +8.9%, SPXC +7.8%, CDNA +5.9%, CSTL +5.2%, MMSI +4.7%, SPSC +4.7, GDYN +4.1%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:34 PM UTC
H
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after resu
COHU +16.2%, AXTI +13.8%, AMZN +8.7%, MPWR +8.5%, FND +6.7%, ILMN +5%, GDYN +4.8%, CSTL +4.6%, CDNA +4.6%, EXPO +3.7%, PTCT +3.3% after results
EARNINGS | Jul 30, 2026, 08:18 PM UTC
L
PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est
PTC Therapeutics (NASDAQ: PTCT ) raises FY2026 sales outlook from $1.080 billion-$1.180 billion to $1.180 billion-$1.280 billion vs $1.196 billion estimate.
EARNINGS | Jul 30, 2026, 08:05 PM UTC
H
PTCT PTC Therapeutics RESULTS: Q2, Q2 product REV $238,819,238.819M, Q2 operating expenses $211.542M, Q2 Net Income $83.496M, Q2 Operating I
PTCT PTC Therapeutics RESULTS: Q2, Q2 product REV $238,819,238.819M, Q2 operating expenses $211.542M, Q2 Net Income $83.496M, Q2 Operating Income $148.977M, Q2 basic EPS $1.01, PTC Therapeutics Earnings Notes:, Outlook F
EARNINGS | Jul 30, 2026, 08:02 PM UTC
L
PTCT PTCT - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PTCT PTCT - PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 30, 2026, 08:01 PM UTC
L
PTCT Reiterate Overweight and $120 PT - continue to have high conviction in shares and see the PKU global opportunity as underappreciated @
PTCT Reiterate Overweight and $120 PT - continue to have high conviction in shares and see the PKU global opportunity as underappreciated @ BARC
EQUITY | Jul 21, 2026, 12:10 PM UTC
H
PTC Therapeutics price target raised to $85 from $82 at RBC Capital
RBC Capital raised the firm's price target on PTC Therapeutics to $85 from $82 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has
RATES | Jul 07, 2026, 11:22 AM UTC